Sarah Delcourte1, Erika Abrial1, Adeline Etiévant2, Renaud Rovera1, Jørn Arnt3, Michael Didriksen4, Nasser Haddjeri1. 1. Inserm, Stem Cell and Brain Research Institute U1208, Univ Lyon, Université Lyon 1, Bron, France. 2. Integrative and Clinical Neurosciences EA481, University of Bourgogne Franche-Comté, Besançon, France. 3. Sunred Pharma Consulting Aps, Solrød Strand, Denmark. 4. Department of Synaptic Transmission 2, H Lundbeck A/S, Valby, Denmark.
Abstract
AIM: Asenapine is a new atypical antipsychotic prescribed for the treatment of psychosis/bipolar disorders that presents higher affinity for serotonergic than dopaminergic receptors. The objective of this study was to investigate its antidepressant-like and antimanic-like properties on relevant animal models of depression and mania and to assess the acute and chronic effect of Asenapine on dorsal raphe nucleus (DRN) 5-HT cell firing activity. METHODS: We assessed the effects of Asenapine using in vivo electrophysiological and behavioral assays in rats. RESULTS: Behavioral experiments showed that Asenapine had no significant effect on immobility time in the forced swim test (FST) in control rats. In the ACTH-treated rats, a model of antidepressant-resistance, Asenapine failed to alter immobility time in the FST. In contrast in the sleep deprivation (SD) model of mania, acute administration of Asenapine significantly decreased the hyperlocomotion of SD rats. In the DRN, acute administration of Asenapine reduced the suppressant effect of the selective 5-HT7 receptor agonist LP-44 and of the prototypical 5-HT1A receptor agonist 8-OH-DPAT on 5-HT neuronal firing activity. In addition, chronic treatment with Asenapine enhanced DRN 5-HT neuronal firing and this effect was associated with an alteration of the 5-HT7 receptor responsiveness. CONCLUSION: These results confirm that Asenapine displays robust antimanic property and effective in vivo antagonistic activity at 5-HT1A/7 receptors.
AIM: Asenapine is a new atypical antipsychotic prescribed for the treatment of psychosis/bipolar disorders that presents higher affinity for serotonergic than dopaminergic receptors. The objective of this study was to investigate its antidepressant-like and antimanic-like properties on relevant animal models of depression and mania and to assess the acute and chronic effect of Asenapine on dorsal raphe nucleus (DRN) 5-HT cell firing activity. METHODS: We assessed the effects of Asenapine using in vivo electrophysiological and behavioral assays in rats. RESULTS: Behavioral experiments showed that Asenapine had no significant effect on immobility time in the forced swim test (FST) in control rats. In the ACTH-treated rats, a model of antidepressant-resistance, Asenapine failed to alter immobility time in the FST. In contrast in the sleep deprivation (SD) model of mania, acute administration of Asenapine significantly decreased the hyperlocomotion of SDrats. In the DRN, acute administration of Asenapine reduced the suppressant effect of the selective 5-HT7 receptor agonist LP-44 and of the prototypical 5-HT1A receptor agonist 8-OH-DPAT on 5-HT neuronal firing activity. In addition, chronic treatment with Asenapine enhanced DRN 5-HT neuronal firing and this effect was associated with an alteration of the 5-HT7 receptor responsiveness. CONCLUSION: These results confirm that Asenapine displays robust antimanic property and effective in vivo antagonistic activity at 5-HT1A/7 receptors.
Authors: David R Thomas; Sergio Melotto; Mario Massagrande; Andrew D Gribble; Phillip Jeffrey; Alexander J Stevens; Nigel J Deeks; Peter J Eddershaw; Susan H Fenwick; Graham Riley; Tania Stean; Claire M Scott; Matthew J Hill; Derek N Middlemiss; Jim J Hagan; Gary W Price; Ian T Forbes Journal: Br J Pharmacol Date: 2003-06 Impact factor: 8.739
Authors: Olivia Frånberg; Monica M Marcus; Vladimir Ivanov; Björn Schilström; Mohammed Shahid; Torgny H Svensson Journal: Psychopharmacology (Berl) Date: 2009-02-07 Impact factor: 4.530
Authors: Y Kim; S McGee; J K Czeczor; A J Walker; R P Kale; A Z Kouzani; K Walder; M Berk; S J Tye Journal: Transl Psychiatry Date: 2016-06-21 Impact factor: 6.222